Core Viewpoint - Shengnuo Biotech (688117.SH) is expected to achieve significant growth in net profit for the first three quarters of 2025, indicating strong business performance and market competitiveness [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 114.20 million to 139.57 million yuan for the first three quarters of 2025, representing an increase of 57.25 million to 82.63 million yuan compared to the same period last year, which is a year-on-year growth of 100.53% to 145.10% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 113.35 million and 138.54 million yuan, with an increase of 59.70 million to 84.89 million yuan year-on-year, translating to a growth rate of 111.26% to 158.21% [1] Business Development - The company's main business is steadily developing, with increasing demand for its peptide raw material business orders, contributing to overall performance improvement [1] - The continuous implementation of production capacity investments is driving the company's strong market competitiveness and sustained profitability [1]

Core Viewpoint - Shengnuo Bio (688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit of between 114 million to 140 million yuan, representing a year-on-year growth of 100.53% to 145.1% [1] Group 1 - The company's main business has shown stable development during the reporting period [1] - The construction of production capacity is gradually being realized, contributing to overall performance improvement [1] - The demand for orders in the peptide raw material business continues to grow, enhancing market competitiveness and sustainable profitability [1]

截至发稿，圣诺生物市值为65亿元。 每经AI快讯，圣诺生物（SH 688117，收盘价：41.58元）10月13日晚间发布业绩预告，成都圣诺生物科 技股份有限公司预计2025年前三季度实现归属于母公司所有者的净利润约1.14亿元~1.4亿元，与上年同 期相比，增加5724.99万元~8262.7万元，同比增加100.53%~145.1%。业绩变动主要原因是，报告期内， 公司主营业务稳定发展，随着投建产能不断落地，公司多肽原料药业务订单需求持续增长，带动公司整 体业绩稳步提升，与同期相比业绩实现较大增长，使得公司保持较强的市场竞争力与持续盈利能力。 2024年1至12月份，圣诺生物的营业收入构成为：医药制造业占比98.91%，其他业务占比1.09%。 （记者 胡玲） 每经头条（nbdtoutiao）——AI技术滥用调查：明星可被"一键换装"，"擦边"内容成流量密码，技术防 线为何形同虚设？ ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-027 成都圣诺生物科技股份有限公司 2025 年前三季度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 二、上年同期业绩情况 公司上年同期归属于母公司所有者的净利润为 5,694.66 万元，归属于母公司 所有者扣除非经常性损益后的净利润为5,365.55万元，利润总额为6,392.10万元， 每股收益为 0.51 元。 三、本期业绩变化的主要原因 报告期内，公司主营业务稳定发展，随着投建产能不断落地，公司多肽原料 药业务订单需求持续增长，带动公司整体业绩稳步提升，与同期相比业绩实现较 大增长，使得公司保持较强的市场竞争力与持续盈利能力。 四、风险提示 1 2025 年 1 月 1 日至 2025 年 9 月 30 日。 （二）业绩预告情况 （1）经财务部门初步测算，成都圣诺生物科技股份有限公司（以下简称"公 司"）预计 2025 年前三季度实现归属于母公司所有者的净利润 11,419.66 ...

每经AI快讯，10月13日，圣诺生物(688117.SH)发布2025年前三季度业绩预告，预计归属于母公司所有 者的净利润为1.14亿元至1.40亿元，同比增加100.53%至145.10%。报告期内，公司主营业务稳定发展， 投建产能陆续落地，多肽原料药业务订单需求持续增长，带动整体业绩稳步提升，市场竞争力与持续盈 利能力增强。 ...

Core Viewpoint - The company expects a net profit of 114 million to 140 million yuan for the first three quarters of 2025, representing a year-on-year growth of 100.53% to 145.10% [1] Group 1: Financial Performance - The company's main business is experiencing stable development, contributing to significant growth in overall performance [1] - The demand for orders in the peptide raw material business continues to grow, driven by the ongoing capacity expansion [1] Group 2: Market Position - The company maintains strong market competitiveness and sustainable profitability due to substantial performance growth compared to the same period last year [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2025-026 成都圣诺生物科技股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 投资者四川发展证券投资基金管理有限公司—四川资本市场纾困发展证券投资基 金合伙企业（有限合伙）保证向本公司提供的信息真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 投资者的身份 □控股股东/实际控制人及其一致行动人 □√其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他______________（请注明） 2.信息披露义务人信息 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | 四川发展证券投资基 金管理有限公司—四 | □ | 控股股东/实控人 | | | 川资本市场纾困发展 | □ | 控股股东/实控人的一致 | □√ 91510100MA6AE3QM76 | | | 行动 ...

| 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | | --- | --- | --- | --- | --- | | 四川发展证券投资基 | □ | 控股股东/实控人 | | | | 金管理有限公司—四 | | | | | | | □ | 控股股东/实控人的一致 | □√ | 91510100MA6AE3QM76 | | 川资本市场纾困发展 | 行动人 | | □ | 不适用 | | 证券投资基金合伙企 | □√ | 其他直接持股股东 | | | | 业（有限合伙） | | | | | 证券代码：688117 证券简称：圣诺生物 公告编号：2025-026 成都圣诺生物科技股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 投资者四川发展证券投资基金管理有限公司—四川资本市场纾困发展证券投资基 金合伙企业（有限合伙）保证向本公司提供的信息真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 投资者的身份 □控股股东/实际控制人及其一致行 ...

Group 1 - The core point of the article is that Shengnuo Bio (688117.SH) has received a notice from Sichuan Development Securities Investment Fund Management Co., Ltd. regarding a share reduction plan by its shareholder, Sichuan Capital Market Relief Development Securities Investment Fund Partnership (Limited Partnership) [1] - Sichuan Development Investment reduced its holdings by 390,000 shares, which accounts for 0.25% of the company's total share capital [1] - Following this reduction, Sichuan Development Investment's shareholding decreased from 11,407,021 shares to 11,016,995 shares, representing a reduction in ownership from 7.25% to 7.00% [1]

Core Viewpoint - As of September 15, a total of 123 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Continuous Net Inflows - The stock with the longest consecutive net inflow is Yunnan Energy Investment, which has seen net buying for 20 consecutive trading days [1] - Other notable stocks with significant consecutive net inflows include COFCO Sugar, Loxley Technology, Wankai New Materials, Guotou Capital, Jinxin Agricultural, China Pacific Insurance, Camel Group, and Saint Noble Biotechnology [1]